论文信息 - De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. - 字舞流文

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

N. Harbeck | O. Gluz | S. Kuemmel | C. Liedtke | T. Reimer | H. Kreipe | E. Grischke | R. Kates | U. Nitz | R. Wuerstlein | H. Forstbauer | C. Schumacher | M. Braun | M. Christgen | J. Potenberg | K. Krauss | H. Fischer | D. Augustin | A. Kohls | A. Stefek | J. Schumacher